Virological response rates for telaprevir‐based hepatitis <scp>C</scp> triple therapy in patients with and without <scp>HIV</scp> coinfection

Abstract

Virological responses of coinfected and monoinfected patients did not differ significantly, but tended to be higher in coinfected patients, who had a 60.6% SVR12 rate. Telaprevir-based triple therapy is a promising option for coinfected patients with well-controlled HIV infection.